Morningstar8d
Boehringer Ingelheim and WHO Foundation join forces to promote equitable access to healthcare and increase efforts for suicide prevention
Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, in partnership with WHO Foundation, today pledged USD 5 million to advance access to quality healthcare ...
Animal Antibacterial and Antibiotics Market Poised for Significant Growth: Projected to Reach USD 6.5 Billion by 2031: - Market Research Intellect
The Animal Antibacterial and Antibiotics Market is being driven by several key factors. Rising livestock production and ...
Medindia9d
Boehringer Ingelheim and WHO Foundation join forces to promote equitable access to healthcare and increase efforts for suicide prevention.
BERLIN, Oct. 15, 2024 /PRNewswire/ -- Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, in partnership with WHO Foundation, today pledged USD 5 million to ...
Zawya4d
More than 300 regional experts gather in Cairo for Boehringer Ingelheim’s Forums
Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term, sustainable perspective. More than 53,000 employees serve over 130 markets in the two business units Human Pharma ...
Financial Post27d
Boehringer Ingelheim partners with NCD Alliance to target Non-Communicable Diseases in underserved communities
Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top ... relating to the approval status and labels of approved products may vary ...
Boehringer Ingelheim: Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two phase III trials in MASH for survodutide
The U.S. FDA Breakthrough Therapy designation is for the treatment of adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate or advanced fibrosis, based on surv ...
Ottumwa Courier8d
Boehringer Ingelheim and WHO Foundation join forces to promote equitable access to healthcare ...
Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, in partnership with WHO Foundation, today pledged USD 5 million to advance access to quality healthcare servic ...
Farmers Weekly29d
First new bluetongue vaccines available for use
Boehringer Ingelheim’s Bultavo 3 is among the first vaccines delivered, along with Virbac’s Syvazul BTV3, while Ceva Animal Health’s Bluevac-3 will be available in the UK from mid-October.
US FDA approves Elanco's treatment for parasitic infections in dogs
The U.S. Food and Drug Administration has approved Elanco Animal Health's oral drug to protect dogs against six parasitic ...